Publications by authors named "A O Ashaye"
Article Synopsis
- Ponatinib and asciminib are both approved for treating chronic-phase chronic myeloid leukemia (CP-CML) in the U.S., specifically for patients who have not responded to other therapies or have the T315I mutation, with ponatinib also available in Europe for this mutation.
- A systematic review identified clinical trials comparing the effectiveness of ponatinib and asciminib for patients who have relapsed or are resistant to treatments, and a statistical analysis was used to compare their response rates after matching patient characteristics.
- Results showed ponatinib had significantly higher response rates than asciminib, particularly in patients with the T315I mutation, indicating that ponatinib may be a more effective treatment option in these cases.
Importance: Primary open-angle glaucoma (POAG) polygenic risk scores (PRSs) continue to be evaluated in primarily European-ancestry populations despite higher prevalence and worse outcomes in African-ancestry populations.
Objective: To evaluate how established POAG PRSs perform in African-ancestry samples from the Genetics in Glaucoma Patients of African Descent (GIGA), Genetics of Glaucoma in Individuals of African Descent (GGLAD), and Million Veteran Program (MVP) datasets and compare these with European-ancestry samples.
Design, Setting, And Participants: This was a multicenter, cross-sectional study of POAG cases and controls from Tanzania, South Africa, Nigeria, Ghana, and the US.
Prcis: Patients' acceptance of glaucoma therapy was high overall in this study, but lower for surgery than for laser or medical therapy. Fear and cost were the leading reasons why patients declined recommended therapy and they were treatment-specific. Cost was the primary reason for declining medical and laser therapy, while fear was the most common reason for declining surgical therapy.
View Article and Find Full Text PDFPrimary open-angle glaucoma (POAG), the leading cause of irreversible blindness worldwide, disproportionately affects individuals of African ancestry. We conducted a genome-wide association study (GWAS) for POAG in 11,275 individuals of African ancestry (6,003 cases; 5,272 controls). We detected 46 risk loci associated with POAG at genome-wide significance.
View Article and Find Full Text PDFIntroduction: ophthalmic genetics is rapidly evolving globally but is still nascent in much of sub-Saharan Africa, with gaps in knowledge about the burden in the region. This study evaluated the burden and manifestations of genetic eye diseases in children in Ibadan, Nigeria.
Methods: this was a hospital-based cross-sectional study in which new and follow-up paediatric eye clinic patients were recruited consecutively at the University College Hospital, Ibadan.